来自MSN9 个月
Sionna raises $182m to double down in cystic fibrosis drug development
One of the most common CFTR mutations—F508del—leads to NBD1 unfolding, which negatively affects CFTR function. Sionna says that its NBD1 stabilisers are designed to restore the function of the ...
The Victoria Advocate1 个月
Sionna Therapeutics Announces Appointment of Laurie Stelzer to its Board of Directors
Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For information about Sionna ...